Results 171 to 180 of about 30,645 (194)
Some of the next articles are maybe not open access.
Journal of Hepatology, 2002
Lamivudine-induced hepatitis B e antigen (HBeAg) seroconversion in patients with chronic hepatitis B was reported to be durable by several studies but controversy still exists. The aim of this study was to evaluate the durability of the responses of lamivudine treatment.Among 53 chronic hepatitis B patients who had acute exacerbation and had finished ...
Chuan-Mo, Lee +7 more
openaire +2 more sources
Lamivudine-induced hepatitis B e antigen (HBeAg) seroconversion in patients with chronic hepatitis B was reported to be durable by several studies but controversy still exists. The aim of this study was to evaluate the durability of the responses of lamivudine treatment.Among 53 chronic hepatitis B patients who had acute exacerbation and had finished ...
Chuan-Mo, Lee +7 more
openaire +2 more sources
Infection, 1991
Acute hepatitis C virus superinfection followed by spontaneous hepatitis B e antigen seroconversion and hepatitis B surface antigen clearance in a patient with chronic type B hepatitis is described. The observations suggests that HCV may exert a suppressive effect on hepatitis B virus.
Y F, Liaw +3 more
openaire +2 more sources
Acute hepatitis C virus superinfection followed by spontaneous hepatitis B e antigen seroconversion and hepatitis B surface antigen clearance in a patient with chronic type B hepatitis is described. The observations suggests that HCV may exert a suppressive effect on hepatitis B virus.
Y F, Liaw +3 more
openaire +2 more sources
Prevalence of HBeAg and HBsAg seroconversion in patients with chronic hepatitis B.
Sbornik lekarsky, 1995In 37 patients with chronic hepatitis B in the stage of active viral replication the authors tried to assess the time of seroconversion of HBeAg to anti-HBe and HBsAg to anti-HBs (21 men, 13 women and 3 boys, mean age of adults 44 years). During the 8-years investigation period seroconversion of HBeAg occurred in 19 of 37 patients (51.3%) which is an ...
J, Stránský +5 more
openaire +1 more source
Viral Immunology, 2014
The major shortcoming of nucleos(t)ide analogue therapy for chronic hepatitis B (CHB) is the frequent requirement for indefinite therapy. Withdrawal of treatment can result in viral rebound with an alanine aminotransferase (ALT) flare leading to hepatic decompensation, while in others this can lead to hepatitis B e antigen (HBeAg) seroconversion.
Shilpa, Chokshi +6 more
openaire +2 more sources
The major shortcoming of nucleos(t)ide analogue therapy for chronic hepatitis B (CHB) is the frequent requirement for indefinite therapy. Withdrawal of treatment can result in viral rebound with an alanine aminotransferase (ALT) flare leading to hepatic decompensation, while in others this can lead to hepatitis B e antigen (HBeAg) seroconversion.
Shilpa, Chokshi +6 more
openaire +2 more sources
Mathematical investigation of HBeAg seroconversion
Published ...Kadelka, Sarah, Ciupe, Stanca M.
openaire +1 more source
[Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients].
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2007To investigate the factors which may affect the rate of HBeAg seroconversion and its durability after long-term lamivudine therapy in chronic hepatitis B patients.81 patients were treated in a phase III clinical trial with lamivudine 100 mg daily for up to 5 years.
Mei, Zhu, Bei, Xu, Guang-bi, Yao
openaire +1 more source
Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi, 2017
Objective: To understand characteristics and influencing factors of reversion of HBeAg in chronic hepatitis B patients with HBeAg sero-conversion, and provide epidemiological evidence for the regular management of chronic hepatitis B patients. Methods: From 2012 to 2014, a cohort study was conducted among the chronic hepatitis B patients with sero ...
L G, Zhu +11 more
openaire +1 more source
Objective: To understand characteristics and influencing factors of reversion of HBeAg in chronic hepatitis B patients with HBeAg sero-conversion, and provide epidemiological evidence for the regular management of chronic hepatitis B patients. Methods: From 2012 to 2014, a cohort study was conducted among the chronic hepatitis B patients with sero ...
L G, Zhu +11 more
openaire +1 more source
HBeAg seroconversion and longterm outcome with interferon-??
Inpharma Weekly, 1996openaire +1 more source
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2011
To investigate the efficacy of Telbivudine and Entecavir for therapy of HBeAg positive chronic hepatitis B for 52 weeks.In this random and control study, the efficacy of Telbivudine and Entecavir treatments were compared in 180 patients with HBeAg positive chronic hepatitis B.The patients were randomly assigned to a daily 600 mg Telbivudine treatment ...
Jing, Huang +6 more
openaire +1 more source
To investigate the efficacy of Telbivudine and Entecavir for therapy of HBeAg positive chronic hepatitis B for 52 weeks.In this random and control study, the efficacy of Telbivudine and Entecavir treatments were compared in 180 patients with HBeAg positive chronic hepatitis B.The patients were randomly assigned to a daily 600 mg Telbivudine treatment ...
Jing, Huang +6 more
openaire +1 more source

